Peptides as Contrast Imaging Agents for MRI and PET

Gly-DArg-DPhe-DPhe-DVal-DLeu-DLys-Gly-hexaDArg

Brian Austen, St George's Hospital, London, UK

Programme:

Monday 3 August (morning and afternoon)

Keynote Speakers

Radiolabelled neuropeptides for cancer imaging
Stephen Mather, Queen Mary University of London, UK

Peptide vectorized magnetic probes for magnetic resonance molecular imaging (MRMI)
Robert Muller, University of Mons, Belgium

Speakers

Rapid radiosynthesis of PET probes for brain imaging
Franklin Aigbirhio, University of Cambridge, UK

Imaging amyloid with PET
David J Brooks, Imperial College London, UK

The first single-step synthesis of the fluorine-18 peptide labelling agent [18F]SFB
Michael A. Carroll, Newcastle University, UK

The labelling of peptides and proteins with metallic radionuclides for PET or SPECT imaging
J R Dilworth, University of Oxford, UK

Peptide-based molecular imaging agents for PET
Adriano Duatti, University of Ferrara, Italy

Title TBA
Tony Gee, GlaxoSmithKline, UK

Development of MRI imaging reagents that bind aggregated beta-amyloid for diagnosis of Alzheimer's Disease
Balpreet Matharu, St George's University of London, UK

Symposium Information

Peptides and peptide derivatives are increasingly playing a role in non-invasive imaging in diagnosis and therapy, particularly in oncology, using PET or MRI. Peptides, in their sequence, contain the specificities required for binding to targets at specific locations in the body, or in discreet pathologies. Even intracellular targets can be imaged with the attachment of cell-penetration peptides. Attached rare-earths enhance the T1 and T2 resolved images obtained by MRI to allow imaging of disease-specific lesions; whereas radiopeptides are imaged by PET.

A variety of speakers will describe recent advances made in this cross-disciplinary research area, which promotes collaborations between physicists, chemists, biologists and clinicians.